Pyridoxine-dependent epilepsy (PDE) is a rare disorder caused by aldehyde dehydrogenase 7 family member A1 (ALDH7A1) deficiency. The present study reported on three Chinese cases of PDE with phenotypic variability for providing further insight into this disease. All three patients presented with recurrent seizures and readily responded to treatment with pyridoxine, in line with the typical symptomology of PDE. The three cases varied in their clinical manifestations with regard to the time of onset, seizure type, EEG findings and mental development. Four ALDH7A1 mutations were identified in Case 1 (c.1008+1G>A and c.871+5G>A) and Case 2 (c.977A>G and c.1463A>G). To the best of our knowledge, the present study was the first to report on the mutations c.871+5G>A and c.1463A>G. Early definitive diagnosis and timely treatment with pyridoxine was the cornerstone of management of PDE. Timely treatment was associated with excellent prognosis. A high index of suspicion in cases and early genetic testing may facilitate early diagnosis of this rare disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609134 | PMC |
| http://dx.doi.org/10.3892/etm.2017.4735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of newborn screening for pyridoxine-dependent epilepsy.
Mol Genet Metab
December 2024
Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address:
Background: Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is a developmental epileptic encephalopathy historically characterized by seizures that are resistant to antiseizure medications. Treatment with pyridoxine and lysine reduction therapies are associated with seizure control and improved developmental outcomes. In rare circumstances, patients have died prior to diagnosis and treatment with pyridoxine, and many patients are diagnosed after six months of age when lysine reduction therapies have limited efficacy.
View Article and Find Full Text PDFDetermination of new biomarkers for diagnosis of pyridoxine dependent epilepsy in human plasma and urine by liquid chromatography-mass spectrometry.
Clin Chim Acta
December 2024
Newborn Screening, Clinical Biochemistry and Clinical Pharmacy Laboratory, Meyer Children's Hospital IRCCS, 50139 Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy. Electronic address:
Article Synopsis
- Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder linked to abnormal lysine metabolism, with current diagnostics relying on unreliable biomarkers that are unstable and technically challenging to analyze.
- A new method was developed using LC-MS/MS to quantify two alternative biomarkers (2-OPP and 6-oxoPIP) from urine and plasma samples, which showed excellent stability and linearity in testing.
- This validated method offers a promising routine diagnostic tool for identifying and monitoring PDE in patients, potentially improving clinical outcomes.
Restricting lysine normalizes toxic catabolites associated with ALDH7A1 deficiency in cells and mice.
Cell Rep
December 2024
Department of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada. Electronic address:
Lysine metabolism converges at α-aminoadipic semialdehyde dehydrogenase (ALDH7A1). Rare loss-of-function mutations in ALDH7A1 cause a toxic accumulation of lysine catabolites, including piperideine-6-carboxylate (P6C), that are thought to cause fatal seizures in children unless strictly managed with dietary lysine reduction. In this study, we perform metabolomics and expression analysis of tissues from Aldh7a1-deficient mice, which reveal tissue-specific differences in lysine metabolism and other metabolic pathways.
View Article and Find Full Text PDFPyridoxine-dependent epilepsy caused by an ALDH7A1 mutation in an infant girl: the first case report in Syria.
BMC Neurol
November 2024
Department of Inherited Metabolic Diseases, Children's University Hospital, Damascus, Syria.
Background: Pyridoxine-dependent epilepsy is primarily characterized by early-onset refractory seizures. This condition can be caused by alpha-aminoadipic semialdehyde dehydrogenase deficiency due to a mutation in the ALDH7A1 gene, leading to the accumulation of certain substances that impact the production of various brain neurotransmitters and enzymes.
Case Presentation: Our report presents the first documented case of pyridoxine dependency in Syria.
[Phenotype of infantile epileptic spasm syndrome in pyridoxin-dependent epilepsy].
Beijing Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Objective: To analyze the clinical diagnosis, treatment, and prognosis of the patients with pyridoxine-dependent epilepsy (PDE) characterized by infantile epileptic spasm syndrome (IESS).
Methods: A total of 75 PDE patients with variants were diagnosed at the Department of Pediatrics of Peking University First Hospital and Peking University People's Hospital from July 2012 to June 2024, and five PDE patients with the phenotype of IESS were selected. The clinical manifestations, treatment, blood biochemistry, metabolic screening, electroencephalogram (EEG), brain magnetic resonance imaging (MRI), and gene testing results of the five PDE patients were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!